Challenges, Advancements, and the Role of Technology

An Outsourcing-Pharma (OSP) article exploring Parkinson’s disease clinical trials, featuring commentary from ICON Central Nervous System (CNS) experts Dr Peter Schueler (Sr VP, Drug Development Services) and Haichen Yang (VP, Global Therapeutic Lead). For neurological research areas, digital endpoints may soon be used as primary endpoints, allowing for in-home trials to be conducted over longer periods of time.

CNS, Pain and Ageing related disorders insights

ICON's experienced neuroscience and drug development teams regularly share their insights in industry publications and through ICON produced content in the form of blogs and whitepapers. Read more content from our experts.

Read more